Matricytosis is a phenotype-specific ECM internalization program dysregulated across macrophages and fibroblasts in pulmonary fibrosis

The human lung is a delicate organ designed for one primary task: to exchange air for life. To do this, it relies on a vast, intricate network of tiny air sacs and the thin, flexible walls that separate them. These walls are not empty space; they are held together and given shape by a complex scaffold of proteins and fibers known as the extracellular matrix. Think of this matrix as the structural framework of a building, providing support and organization. In a healthy lung, this framework is constantly being maintained. Old, worn-out parts are broken down and removed, while new parts are added to replace them, keeping the tissue flexible and functional. This balance between building up and tearing down is essential. When this balance tips, the result can be a devastating condition called idiopathic pulmonary fibrosis. In this disease, the lung's scaffolding becomes thick, stiff, and scarred, making it impossible for the organ to stretch and breathe properly. For decades, scientists have focused almost entirely on the "building" side of this equation, believing that the disease is caused by cells producing too much of this scar tissue.

However, a new study suggests that the story is incomplete. It proposes that the problem might not just be about building too much, but also about failing to clear away the old material. The researchers investigated a specific process they call matricytosis, which is simply the act of cells swallowing and digesting pieces of the extracellular matrix. They wanted to know if this cleanup crew was working correctly in the lungs of people with fibrosis, and if different types of cells were doing the job differently. By examining human lung cells and tissue samples, they discovered that the cleanup process is highly dependent on which cell is doing the work and what state that cell is in. In a healthy lung, certain cells are very good at eating up old matrix, but in the diseased lung, this ability changes in surprising ways. Some cells stop cleaning up effectively, while others start cleaning up too much, but in a way that seems to drive the disease forward rather than fix it. This shift in perspective suggests that treating fibrosis might require not just stopping the overproduction of scar tissue, but also helping the lung's natural cleanup systems work better.

The researchers began by creating a way to watch this cleanup process happen in real time. They took human lung cells and grew them in a dish, allowing them to lay down a layer of their own extracellular matrix. They then removed the cells, leaving behind a clean, decellularized scaffold that mimicked the lung's natural environment. To see if other cells could eat this material, they labeled the matrix with a special dye that glows brighter when it enters an acidic environment, like the inside of a cell's stomach, known as a lysosome. When they added immune cells called macrophages and structural cells called fibroblasts to this labeled matrix, they could watch the cells swallow the material and break it down. The glowing dye confirmed that the cells were indeed taking the matrix inside and sending it to their digestive compartments. This proved that matricytosis is a real, active process in human lung cells.

Next, the team explored how this process changes when cells are in a diseased state. They found that the ability to clean up the matrix depends heavily on the specific type of cell and its current condition. In the case of macrophages, which are the lung's primary scavengers, the disease seems to impair their ability to do their job. When the researchers looked at macrophages that were in a state similar to what is seen in fibrosis, these cells showed a marked decrease in their ability to swallow and digest the matrix. This mirrors what is known about these cells in fibrosis, where they often struggle to clear away dead cells or bacteria. The study suggests that this failure to clear the extracellular matrix contributes to the buildup of scar tissue.

In a twist that challenged previous assumptions, the researchers found that fibroblasts, the cells responsible for building the matrix, behave differently. In a healthy state, fibroblasts are not very active at eating matrix. However, when these cells become activated and turn into myofibroblasts—a state associated with fibrosis—they become much more aggressive at swallowing the matrix. This might seem like a good thing, as if the cells are trying to clean up the mess they made. But the study indicates that this increased activity is part of a broader, invasive program. These activated fibroblasts are not just cleaning; they are remodeling the tissue in a way that promotes further scarring and invasion into healthy areas. The researchers observed that this aggressive cleanup behavior is linked to specific molecular pathways that allow the cells to move through and reshape the tissue, similar to how cancer cells invade surrounding areas.

To understand how this plays out in the actual human body, the team looked at data from thousands of cells taken from healthy lungs and lungs with fibrosis. They used advanced mapping techniques to see which cells were active in different parts of the tissue. The results showed that in healthy lungs, macrophages are the dominant cells responsible for eating the matrix, and they are spread evenly throughout the tissue. In fibrotic lungs, however, the landscape changes. While macrophages still have the capacity to eat matrix, they are found in different locations, often clustered near the airways and the areas of active scarring. More importantly, the study found that the fibroblasts in the scarred regions are the ones showing the highest levels of this aggressive matrix-eating behavior. These cells are located right in the middle of the fibrotic niches, the areas where the disease is most active. This suggests that the fibroblasts are not just passive builders of scar tissue but are active participants in reshaping the lung's structure, potentially driving the disease forward through their own cleanup efforts.

The researchers also tested whether the environment itself influences this behavior. They used slices of lung tissue from patients with fibrosis, which had been stripped of their cells but kept their natural, scarred structure. When they placed healthy cells onto these fibrotic slices, the cells changed their behavior. The fibrotic matrix seemed to override the cells' natural tendencies, altering how they ate and interacted with the material. This finding highlights that the disease is not just about the cells themselves, but about the conversation between the cells and their environment. The stiff, scarred matrix of a fibrotic lung sends signals that change how cells behave, potentially turning a normal cleanup process into a destructive one.

The study concludes that the accumulation of scar tissue in pulmonary fibrosis is likely a result of a broken balance. It is not simply that too much matrix is being made, but that the system for removing it is dysregulated. Macrophages, the usual cleanup crew, are failing to do their job effectively, while fibroblasts, the builders, are taking over the cleanup role in a way that fuels the disease. This dual failure creates a cycle where old matrix is not removed, and new matrix is added in a chaotic, invasive manner. The researchers also noted that existing drugs used to treat fibrosis can influence this process, suggesting that these medications might work partly by affecting how cells eat and remodel the matrix. By identifying matricytosis as a key player in the disease, the study opens up new possibilities for treatment. Instead of just trying to stop the production of scar tissue, future therapies might focus on restoring the balance of cleanup, helping the right cells do their job and stopping the wrong cells from taking over. This shift in understanding reframes fibrosis as a disease of both overproduction and failed clearance, offering a more complete picture of what goes wrong in the lungs and how it might be fixed.